Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer’s Cardura XL Clears FDA For Benign Prostatic Hyperplasia

This article was originally published in The Pink Sheet Daily

Executive Summary

The extended-release formulation of doxazosin has a narrower indication than the immediate-release formulation but allows for less frequent dose titration. Both formulations are once-daily.

You may also be interested in...

Andrx Drops Cardura XL Distribution Deal In Move Away From Brand Business

Company moves to terminate a supply and distribution deal with Pfizer because the BPH agent failed to receive FDA approval by Dec. 31, 2004. Andrx is divesting its brand business to focus on its "core competencies" of controlled-release formulation development and distribution.

Pfizer Cardura XL “Approvable”

Pfizer will "respond promptly" to FDA's "approvable" letter for Cardura XL, marketing partner Andrx says.

Natrecor Use Should Be Limited, Independent Panel Convened By J&J Says

The cardiologist panel calls for use of the congestive heart failure therapy to be "strictly limited" to patients that present with symptoms in the hospital setting. The expert panel also recommends that Scios "immediately undertake" a professional educational campaign about Natrecor's appropriate uses.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts